Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dhaval Shah (NPI 1063743722)

Field	Value
Entity Type	Individual
Organization	Dhaval Shah
Address	4701 Ogletown Stanton Rd
City	Newark
State	DE
ZIP	19713
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 20, 2010

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the sole payer presence on file: Total Medicare revenue is $2.5M and there is no Medicaid billing on file, indicating an effectively single‑payer (Medicare) practice for the datasets shown. Analysts should treat Medicaid-derived benchmarks as unavailable for this NPI and focus competitive comparisons to Medicare-only activity.

Revenue is highly concentrated in a small set of infusion drugs: the precomputed top 3 Medicare codes (J9271, J9299, J9144) account for 80.5% of this provider’s total Medicare revenue. Those three codes individually generate $1.2M (J9271), $477.1K (J9299), and $355.7K (J9144), showing the practice’s financial dependence on checkpoint inhibitors and monoclonal antibody therapies.

The code mix identifies an oncology infusion–centric operation: the top revenue drivers are J9271 (pembrolizumab), J9299 (nivolumab) and J9144 (daratumumab), supplemented by chemotherapy administration codes such as 96413 and add‑on/infusion codes like 96417 and G0498. This pattern indicates the provider delivers high-volume biologic/immunotherapy infusions and routine chemotherapy administration in an outpatient/clinic setting rather than primarily procedural or surgical oncology.

Competitive standing for pembrolizumab (J9271) is relatively strong nationally: the provider reports 27.2K claims and $1.2M revenue for J9271 and ranks #171 of 1841 nationally (90th percentile; typical, unremarkable volume for this code). In plain terms, the practice is a high‑volume national user of pembrolizumab compared with peers, even though the dataset labels the observed volume as "typical, unremarkable."

For J9299 and J9144 the provider’s national positions are modest-to-moderate: J9299 shows 19.9K claims, $477.1K revenue and ranks #167 of 505 providers (67th percentile; typical, unremarkable volume), while J9144 shows 9.4K claims, $355.7K revenue and ranks #241 of 615 providers (59th percentile; typical, unremarkable volume). These percentiles indicate the provider is an active but not dominant national participant for nivolumab and daratumumab relative to the available peer pools.

Office E/M activity is notable at the established visit level: 99213 appears with 622 claims, $41.7K revenue and ranks #18144 of 457151 providers (96th percentile; notably above typical national volume), while higher‑level E/M codes such as 99214 and 99215 are present at more typical percentiles. The elevated 99213 percentile suggests a steady outpatient visit throughput that supports the infusion practice model and patient follow‑up workload.

Ancillary infusion and administration codes corroborate an in‑clinic infusion service with community/home continuation capabilities: 96413 (523 claims, $54.9K, rank #608 of 7514, 92th percentile; typical, unremarkable volume), G0498 (69 claims, $9.8K, rank #222 of 896, 74th percentile; typical, unremarkable volume), and 96365 (111 claims, $5.6K, rank #3344 of 8873, 62th percentile; typical, unremarkable volume) are all reported. Presence of G0498 (office pump with continuation into the community) specifically signals the clinic provides infusion initiation with at‑home continuation for some patients.

This NPI shows established tenure that aligns with its billing profile: NPI enumerated 2010-01-20 (~16 years ago), which supports the interpretation that the current Medicare billing patterns reflect a stable, mature outpatient oncology infusion practice rather than a transient or newly established operation. Analysts evaluating growth or market share should consider the long runway when comparing activity year-over-year.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

48 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,200	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	19,880	$20	$477.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,360	$40	$355.7K
J0897	Injection, denosumab, 1 mg	6,660	$20	$126.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$110	$54.9K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	540	$100	$51.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	620	$70	$41.7K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	100	$350	$33.6K
J1437	Injection, ferric derisomaltose, 10 mg	1,900	$20	$30.4K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	160	$140	$21.7K

Showing 1–10 of 48

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 48 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Dhaval Shah — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

48 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	17,600	$40	$992.4K
J9144	3	10	9,360	$40	$420.8K
J9299	1	10	14,300	$20	$329.6K
J0897	15	60	3,360	$20	$132.9K
Q5122	2	10	400	$100	$61.8K
J0881	4	10	25,410	$1	$57.7K
J1437	3	10	1,800	$20	$47.1K
J1454	4	10	90	$340	$38.1K
96413	7	30	280	$100	$36.6K
J9217	12	30	160	$130	$31.1K

Showing 1–10 of 48

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dhaval Shah, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Jamal Misleh	DE	Hematology & Oncology Physician	$6.8M	$0
Gregory Masters	DE	Medical Oncology Physician	$2.3M	$0
Evan Lapinsky	DE	Hematology & Oncology Physician	$1.7M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Amy Mcghee Jez	DE	Hematology & Oncology Physician	$1.1M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Roberto Ferro Valdes	SD	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Dhaval Shah, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Columbus Medical Services, LLC	DE	Case Management Agency	$0	$18.7M
Christiana Care Health Services Inc	DE	Hospitalist Physician	$0	$13.6M
Caritas Home Health Services, Inc	DE	Home Health Agency	$0	$11.2M
Delaware Center For Maternal Fetal Medicine Of Christiana Care	DE	Maternal & Fetal Medicine Physician	$0	$9.8M
Christiana Care Health Services Inc	DE	Neonatal-Perinatal Medicine Physician	$0	$8.9M
Christiana Care Quality Partners	DE	Urgent Care Clinic/Center	$0	$7M
Mid-atlantic Behavioral Health, LLC	DE	Intellectual & Developmental Disabilities Psychologist	$0	$6.5M
First State Orthopaedics, PA	DE	Orthopaedic Surgery Physician	$0	$6M
Autism Delaware	DE	Intellectual & Developmental Disabilities Psychologist	$0	$5.8M

Dhaval Shah — Billing Profile & Reimbursement Data

Sign up for Dhaval Shah — Billing Profile & Reimbursement Data policy alerts

Dhaval Shah — Billing Profile & Reimbursement Data

Sign up for Dhaval Shah — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References